Earnings History Data for Lyra Therapeutics, Inc. (LYRA) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Lyra Therapeutics, Inc.
Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and consistently deliver medicines directly to the affected tissue. Its initial product candidates consist LYR-210 and LYR-220 which are in clinical stage. Lyra Therapeutics Inc. is based in Watertown, Mass.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-11-2024 | PM | LYRA | Lyra Therapeutics, Inc. | 17.52 | -0.18 | -0.23 | -0.27 | Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M [11/13/2024 3:03 AM] |
0.1985 | -0.08 (-27.82%) |
0.27 | -0.01 (-2.87%) |
0.19 - 6.79 | 7,020,902 | 1,110,000 | 10,855 | ||
| 30-04-2024 | AH | LYRA | Lyra Therapeutics | 282.00 | -0.35 | -0.26 | 0.00 | Lyra Therapeutics GAAP EPS of -$0.35 misses by $0.08, revenue of $0.53M beats by $0.18M [4/30/2024 5:35 PM] |
5.40 | 0.24 (4.65%) |
5.16 | 0.0 (0.00%) |
2.36 - 6.79 | 398,155 | 230,000 | 2,312 | ||
| 21-03-2024 | AH | LYRA | Lyra Therapeutics | 317.00 | -0.22 | -0.33 | 0.00 | Lyra Therapeutics reports Q4 results [3/21/2024 5:05 PM] |
6.30 | 0.23 (3.79%) |
6.25 | 0.18 (2.97%) |
1.86 - 6.71 | 546,528 | 270,000 | 661 | ||
| 07-11-2023 | AH | LYRA | Lyra Therapeutics | 155.00 | -0.27 | -0.33 | 0.00 | Lyra Therapeutics GAAP EPS of -$0.27, revenue of $544M [11/7/2023 6:02 PM] |
2.90 | -0.03 (-1.02%) |
0.0 | 0.0 (0.00%) |
1.86 - 5.25 | 116,415 | 90,000 | 0 | ||
| 12-05-2023 | PM | LYRA | Lyra Therapeutics | 82.00 | -0.44 | -0.36 | 0.00 | Lyra Therapeutics GAAP EPS of -$0.44, revenue of $0.41M [5/12/2023 9:27 AM] |
2.67 | -0.13 (-4.64%) |
2.92 | 0.12 (4.29%) |
1.86 - 6.99 | 42,941 | 30,000 | 1,111 | ||
| 09-08-2022 | PM | LYRA | Lyra Therapeutics, Inc. | 189.04 | -0.43 | -0.34 | -0.85 | Lyra Therapeutics GAAP EPS of -$0.43, revenue of $0.4M [8/9/2022 8:32 AM] |
6.55 | -0.01 (-0.15%) |
6.23 | -0.33 (-5.03%) |
3.30 - 9.98 | 18,476 | 50,000 | 151 | ||
| 09-03-2022 | PM | LYRA | Lyra Therapeutics, Inc. | 62.03 | -1.05 | -0.82 | -0.46 | Lyra Therapeutics GAAP EPS of -$3.35 misses by $0.23 [3/9/2022 7:52 AM] |
4.20 | -0.10 (-2.32%) |
0.0 | 0.0 (0.00%) |
3.30 - 14.92 | 7,057 | 30,000 | 0 | ||
| 09-11-2021 | AH | 4:05 PM ET (Nov 9) |
LYRA | Lyra Therapeutics, Inc. | 96.86 | -0.85 | -0.71 | -0.49 | Lyra Therapeutics EPS misses by $0.12, misses on revenue [11/9/2021 4:36 PM] |
6.92 | 0.13 (1.95%) |
6.95 | 0.16 (2.36%) |
5.83 - 16.50 | 48,341 | 50,000 | 1,200 | |
| 09-08-2021 | AH | 4:05 PM ET (Aug 9) |
LYRA | Lyra Therapeutics, Inc. | 83.73 | -0.85 | -0.61 | -0.56 | Lyra Therapeutics EPS misses by $0.26 [8/9/2021 4:21 PM] |
6.66 | -0.03 (-0.45%) |
6.97 | 0.0 (0.00%) |
5.83 - 16.50 | 22,513 | 40,000 | 240 | |
| 11-05-2021 | AH | 4:05 PM ET (May 11) |
LYRA | Lyra Therapeutics, Inc. | 109.02 | -0.60 | -0.48 | -18.70 | Lyra Therapeutics EPS misses by $0.12 [5/11/2021 4:18 PM] |
8.01 | -0.09 (-1.11%) |
8.10 | 0.0 (0.00%) |
7.62 - 17.49 | 75,931 | 80,000 | 253 | |
| 09-03-2021 | AH | 4:05 PM ET (Mar 9) |
LYRA | Lyra Therapeutics, Inc. | 176.58 | -0.46 | -0.61 | 0.00 | Lyra Therapeutics EPS misses by $0.58 [3/9/2021 4:28 PM] |
13.63 | -0.97 (-6.64%) |
14.60 | 0.0 (0.00%) |
8.76 - 22.00 | 107,862 | 143,024 | 163 | |
| 10-11-2020 | AH | LYRA | Lyra Therapeutics, Inc. | 142.00 | -0.49 | -0.48 | 0.00 | Lyra Therapeutics EPS misses by $0.05 [11/10/2020 4:44 PM] |
10.82 | -0.04 (-0.41%) |
0.0 | 0.0 (0.00%) |
10.37 - 22.00 | 28,671 | 42,696 | 0 | ||
|
|
||||||||||||||||||
| 10-11-2020 | AH | LYRA | Lyra Therapeutics, Inc. | 139.20 | -0.49 | -0.48 | 0.00 | Lyra Therapeutics EPS misses by $0.05 [11/10/2020 4:44 PM] |
10.82 | -0.04 (-0.41%) |
0.0 | 0.0 (0.00%) |
10.37 - 22.00 | 28,671 | 42,696 | 0 | ||
|
|
||||||||||||||||||
| 05-08-2020 | AH | 4:05 PM ET (Aug 5) |
LYRA | Lyra Therapeutics, Inc. | 173.19 | -0.56 | -0.37 | 0.00 | Lyra Therapeutics EPS misses by $0.21 [8/5/2020 4:25 PM] |
13.69 | -0.27 (-1.93%) |
14.30 | 0.34 (2.44%) |
10.44 - 22.00 | 14,823 | 86,112 | 776 | |
|
|
||||||||||||||||||